摘要

Glioblastoma multiforme (GBM) is a highly malignant type of brain tumor found in humans. GBM cells reproduce quickly, and the median survival time for patients after therapy is approximately 1 year with a high relapse rate. Current therapies and diagnostic tools for GBM are limited; therefore, we searched for a more favorable therapeutic target or marker protein for both therapy and diagnosis. We used mass spectrometry (MS) analysis to identify GBM-associated marker proteins from human plasma and GBM cell cultures. Additional plasma and 52 brain tissues obtained from patients with gliomas were used to validate the association rate of serum amyloid A1 (SAA1) in different grades of gliomas and its distribution in tumors. Microarray database analysis further validated the coefficient of SAA1 levels in gliomas. The cellular mechanisms of SAA1 in GBM proliferation and infiltration were investigated in vitro. We analyzed the correlation between SAA1 and patients' medication requirement to demonstrate the clinical effects of SAA1 in GBM. SAA1 was identified from MS analysis, and its level was revealed to be correlated with the disease grade, clinical severity, and survival rate of patients with gliomas. In vitro cultures, including GBM cells and normal astrocytes, revealed that SAA1 promotes cell migration and invasion through integrin αVβ3 to activate the Erk signaling pathway. Magnetic resonance imaging and tumor region-specific microarray analysis identified a correlation between SAA1 and GBM cell infiltration in patients. In summary, our results demonstrate that SAA1 in combination with integrin αV and β3 can serve as an indicator of high glioblastoma risk. We also identified the cellular mechanisms of SAA1 contributing to GBM progression, which can serve as the basis for future GBM therapy.
原文英語
頁(從 - 到)756-771
頁數16
期刊Molecular Oncology
12
發行號5
DOIs
出版狀態已發佈 - 五月 1 2018

指紋

Glioblastoma
Amyloid
Integrins
Serum
Glioma
Microarray Analysis
Mass Spectrometry
Therapeutics
Brain Neoplasms
Astrocytes
Cell Movement
Blood Proteins
Neoplasms
Survival Rate
Cell Culture Techniques
Magnetic Resonance Imaging
Databases
Recurrence

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cancer Research

引用此文

@article{31ea2963be7d4c479a09d2d52cfcad96,
title = "Serum amyloid A1 in combination with integrin αVβ3 increases glioblastoma cells mobility and progression",
abstract = "Glioblastoma multiforme (GBM) is a highly malignant type of brain tumor found in humans. GBM cells reproduce quickly, and the median survival time for patients after therapy is approximately 1 year with a high relapse rate. Current therapies and diagnostic tools for GBM are limited; therefore, we searched for a more favorable therapeutic target or marker protein for both therapy and diagnosis. We used mass spectrometry (MS) analysis to identify GBM-associated marker proteins from human plasma and GBM cell cultures. Additional plasma and 52 brain tissues obtained from patients with gliomas were used to validate the association rate of serum amyloid A1 (SAA1) in different grades of gliomas and its distribution in tumors. Microarray database analysis further validated the coefficient of SAA1 levels in gliomas. The cellular mechanisms of SAA1 in GBM proliferation and infiltration were investigated in vitro. We analyzed the correlation between SAA1 and patients' medication requirement to demonstrate the clinical effects of SAA1 in GBM. SAA1 was identified from MS analysis, and its level was revealed to be correlated with the disease grade, clinical severity, and survival rate of patients with gliomas. In vitro cultures, including GBM cells and normal astrocytes, revealed that SAA1 promotes cell migration and invasion through integrin αVβ3 to activate the Erk signaling pathway. Magnetic resonance imaging and tumor region-specific microarray analysis identified a correlation between SAA1 and GBM cell infiltration in patients. In summary, our results demonstrate that SAA1 in combination with integrin αV and β3 can serve as an indicator of high glioblastoma risk. We also identified the cellular mechanisms of SAA1 contributing to GBM progression, which can serve as the basis for future GBM therapy.",
keywords = "glioblastoma multiform, integrin αVβ3, invasion, metastasis, serum amyloid A1",
author = "Lin, {Ching Yu} and Yang, {Shun Tai} and Shen, {Shing Chuan} and Hsieh, {Yi Chen} and Hsu, {Fei Ting} and Chen, {Cheng Yu} and Chiang, {Yung Hsiao} and Chuang, {Jian Ying} and Chen, {Kai Yun} and Hsu, {Tsung I.} and Leong, {Wan Chong} and Su, {Yu Kai} and Lo, {Wei Lun} and Yeh, {Yi Shian} and Patria, {Yudha Nur} and Shih, {Hsiu Ming} and Chang, {Che Chang} and Chou, {Szu Yi}",
year = "2018",
month = "5",
day = "1",
doi = "10.1002/1878-0261.12196",
language = "English",
volume = "12",
pages = "756--771",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "wiley",
number = "5",

}

TY - JOUR

T1 - Serum amyloid A1 in combination with integrin αVβ3 increases glioblastoma cells mobility and progression

AU - Lin, Ching Yu

AU - Yang, Shun Tai

AU - Shen, Shing Chuan

AU - Hsieh, Yi Chen

AU - Hsu, Fei Ting

AU - Chen, Cheng Yu

AU - Chiang, Yung Hsiao

AU - Chuang, Jian Ying

AU - Chen, Kai Yun

AU - Hsu, Tsung I.

AU - Leong, Wan Chong

AU - Su, Yu Kai

AU - Lo, Wei Lun

AU - Yeh, Yi Shian

AU - Patria, Yudha Nur

AU - Shih, Hsiu Ming

AU - Chang, Che Chang

AU - Chou, Szu Yi

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Glioblastoma multiforme (GBM) is a highly malignant type of brain tumor found in humans. GBM cells reproduce quickly, and the median survival time for patients after therapy is approximately 1 year with a high relapse rate. Current therapies and diagnostic tools for GBM are limited; therefore, we searched for a more favorable therapeutic target or marker protein for both therapy and diagnosis. We used mass spectrometry (MS) analysis to identify GBM-associated marker proteins from human plasma and GBM cell cultures. Additional plasma and 52 brain tissues obtained from patients with gliomas were used to validate the association rate of serum amyloid A1 (SAA1) in different grades of gliomas and its distribution in tumors. Microarray database analysis further validated the coefficient of SAA1 levels in gliomas. The cellular mechanisms of SAA1 in GBM proliferation and infiltration were investigated in vitro. We analyzed the correlation between SAA1 and patients' medication requirement to demonstrate the clinical effects of SAA1 in GBM. SAA1 was identified from MS analysis, and its level was revealed to be correlated with the disease grade, clinical severity, and survival rate of patients with gliomas. In vitro cultures, including GBM cells and normal astrocytes, revealed that SAA1 promotes cell migration and invasion through integrin αVβ3 to activate the Erk signaling pathway. Magnetic resonance imaging and tumor region-specific microarray analysis identified a correlation between SAA1 and GBM cell infiltration in patients. In summary, our results demonstrate that SAA1 in combination with integrin αV and β3 can serve as an indicator of high glioblastoma risk. We also identified the cellular mechanisms of SAA1 contributing to GBM progression, which can serve as the basis for future GBM therapy.

AB - Glioblastoma multiforme (GBM) is a highly malignant type of brain tumor found in humans. GBM cells reproduce quickly, and the median survival time for patients after therapy is approximately 1 year with a high relapse rate. Current therapies and diagnostic tools for GBM are limited; therefore, we searched for a more favorable therapeutic target or marker protein for both therapy and diagnosis. We used mass spectrometry (MS) analysis to identify GBM-associated marker proteins from human plasma and GBM cell cultures. Additional plasma and 52 brain tissues obtained from patients with gliomas were used to validate the association rate of serum amyloid A1 (SAA1) in different grades of gliomas and its distribution in tumors. Microarray database analysis further validated the coefficient of SAA1 levels in gliomas. The cellular mechanisms of SAA1 in GBM proliferation and infiltration were investigated in vitro. We analyzed the correlation between SAA1 and patients' medication requirement to demonstrate the clinical effects of SAA1 in GBM. SAA1 was identified from MS analysis, and its level was revealed to be correlated with the disease grade, clinical severity, and survival rate of patients with gliomas. In vitro cultures, including GBM cells and normal astrocytes, revealed that SAA1 promotes cell migration and invasion through integrin αVβ3 to activate the Erk signaling pathway. Magnetic resonance imaging and tumor region-specific microarray analysis identified a correlation between SAA1 and GBM cell infiltration in patients. In summary, our results demonstrate that SAA1 in combination with integrin αV and β3 can serve as an indicator of high glioblastoma risk. We also identified the cellular mechanisms of SAA1 contributing to GBM progression, which can serve as the basis for future GBM therapy.

KW - glioblastoma multiform

KW - integrin αVβ3

KW - invasion

KW - metastasis

KW - serum amyloid A1

UR - http://www.scopus.com/inward/record.url?scp=85045848628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045848628&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12196

DO - 10.1002/1878-0261.12196

M3 - Article

VL - 12

SP - 756

EP - 771

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 5

ER -